IMMX reports 89% CR across all NEXICART-2 patients but omits IRC confirmation and denominator details

What happened

On Sept 29, 2026, Immix Biopharma announced an interim update for NEXICART-2 stating an 89% complete response (CR) rate across all patients and that 100% (25/25) of new patients were either in CR or MRD-negative, with 21/25 in CR and the remaining 4/25 MRD-negative. The release frames this as potential best-in-class for relapsed/refractory AL amyloidosis and suggests MRD negativity could lead to up to 98% CR. However, the announcement does not specify whether the 89% CR rate is investigator-assessed or independently confirmed, and it does not clearly reconcile the prior discrepancy between the SEC-filed 75% IRC-confirmed CR (15/20) and the May 2026 deck's 95% CR (19/20) or the denominator ambiguity (n=40 vs 45). Based on the numbers, the implied total cohort appears to be approximately 45 patients, with prior 20 patients contributing 19 CR and new 25 contributing 21 CR, yielding 40 CR (89%), but the missing 4 new patients are MRD-negative and not yet CR, which is a meaningful distinction. No independent review committee data or safety/durability update is provided in the snippet, leaving the key question of regulatory-grade response unresolved.

Implication

The 89% CR rate, if confirmed by independent review on a well-defined 45-patient cohort, would significantly exceed the master report's bull-case threshold of >=90% IRC-CR on >=40 patients, but the current release lacks that confirmation and may be mixing investigator and MRD-negative outcomes. The financial and strategic context remains unchanged: IMMX is pre-revenue with a $100M ATM overhang and prior SEC-filed 75% IRC-CR, so the market will likely reward the news but with skepticism until the next SEC filing. For investors holding or considering a position, the update reduces binary risk modestly but does not eliminate it; the stock may trade toward the $13.50 trim level on momentum but could retrace if the IRC rate comes in near 75% or if the denominator is smaller than 45. The most prudent action is to maintain the WAIT stance and use any spike toward $13.50 as a trimming opportunity, while reassessing entry near $7.50 if the next update provides IRC-confirmed CR >=90% and no new safety signals. Monitoring points include the SEC filing for actual IRC adjudication, clarity on total enrolled/evaluable patients, conversion of MRD-negative patients to CR over time, and any reactivation of ATM sales.

Thesis delta

Prior thesis rated the stock a WAIT due to unresolved IRC-confirmed CR discrepancy and denominator ambiguity. This interim update shows an 89% CR headline across all patients, but the missing IRC confirmation and lack of denominator clarity mean the core underwriting issue is only partially addressed. The thesis remains WAIT, with a slightly higher probability of bullish resolution if the next SEC filing confirms >=90% IRC-CR on >=40 patients; otherwise the bear case of ~75% IRC-CR persists.